University of Miami Sylvester Comprehensive Cancer Center
Relapsed/Refractory ALL: Both Inotuzumab and Blinatumomab Are Superior to Standard Chemotherapy With Regards to Remission Rates and Survival
Comments 0
Login to view comments.
Click here to Login
